Search | Clinical Trials Finder

Conditions: Mood Disorders, Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premenstrual Dysphoric Disorder
Interventions: PH80, Placebo intranasal spray; Drug
Lead sponsor: Pherin Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Premenstrual Dysphoric Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Richmond, Virginia

Conditions: PMDD, Stress, Mood
Interventions: Sertraline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy, Premenstrual Dysphoric Disorder, Premenstrual Syndrome
Interventions: Mixhers HERTIME, Placebo; Dietary Supplement
Lead sponsor: Midwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Glendale, Arizona

Conditions: Bipolar Disorder
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Premenstrual Dysphoric Disorder
Interventions: LWT+AM BWL, EWT+PM BWL; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Premenstrual Dysphoric Disorder, Premenstrual Syndrome
Interventions: fluoxetine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Depressive Disorder, Healthy, Mental Disorders, Mood Disorders
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premenstrual Dysphoric Disorder
Interventions: Individualized laboratory test; Procedure
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions: Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premenstrual Dysphoric Disorder
Interventions: Continuous OC (EE/DROS), Intermittent OC (EE/DROS), placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Premenstrual Syndrome, Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bipolar Disorder, Mental Health
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Premenstrual Syndrome, Menstruation Disturbances
Interventions: Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premenstrual Dysphoric Disorder
Interventions: Levetiracetam; Drug
Lead sponsor: Berkshire Health Systems; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Pittsfield, Massachusetts

Conditions: Premenstrual Syndrome, Premenstrual Dysphoric Disorder, Premenstrual Tension, Menstrual Related Mood Disorder
Interventions: EnBrace HR Softgel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 52 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Premenstrual Dysphoric Disorder (PMDD)
Interventions: sertraline 50 mg daily, Placebo Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Charlottesville, Virginia

Conditions: PMDD, Premenstrual Dysphoric Disorder (PMDD), Premenstrual Syndrome-PMS, Premenstrual Syndrome, Menstrual Cycle
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Premenstrual Syndrome
Interventions: Measures of calcium and bone turnover; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Mood Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1984
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Perimenopause, PMDD
Interventions: transcutaneous auricular neurostimulation (tAN); Device
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Premenstrual Syndrome, Premenstrual Dysphoric Disorder, Dysmenorrhea, Endometriosis, Perimenopause, Menopause, Pelvic Pain
Interventions: Lutea Transcranial Direct Current Stimulation (tDCS) Device, Samphire Guided Care Program; Device · Behavioral
Lead sponsor: Samphire Group, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Hormonal Causes of Menstrual-Related Mood Disorders

Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder

Stress & Premenstrual Symptoms Study

The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

Menstrual Effects On Mood Symptoms in Bipolar Disorder

Alternative Treatments for Premenstrual Dysphoric Disorder

The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder

The Effect of GnRH on Pitutitary Hormones in Menstrual-Cycle Mood Related Disorders

Premenstrual Hormonal and Affective State Evaluation (PHASE) Project

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)

Combined Hormone Replacement in Menstrually-Related Mood Disorders

Reproductive Function and Mood in Women With Bipolar Disorder

A Treatment Study for Premenstrual Syndrome (PMS)

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

Identification and Validation of Epigenetic Biomarkers of PMDD

Altered Calcium and Vitamin D in PMDD or Severe PMS

Study of Premenstrual Syndrome and Premenstrual Dysphoria

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life